Genmab and Incyte announced a clinical trial collaboration on October 25, 2026, to evaluate two investigational cancer therapies alongside chemotherapy in patients with advanced colorectal cancer carrying the KRAS G12D mutation. Genmab will lead the planned Phase 1/2 study, which will combine its antibody therapeutic petosemtamab with Incyte’s INCB161734.
Key Takeaways
- The planned study targets advanced colorectal cancer with the KRAS G12D mutation.
- Genmab will lead testing of petosemtamab and INCB161734 alongside chemotherapy.
- The collaboration is a clinical development step, not evidence that the combination improves patient outcomes.
Table of Contents
Genmab and Incyte outline Phase 1/2 trial
The collaboration brings together an investigational asset from each company to test a combination treatment for a genetically defined group of colorectal cancer patients. The proposed regimen includes both therapies and chemotherapy, rather than either investigational drug alone.
The announcement establishes the companies’ development plan; it does not present clinical results for the combination. Whether the regimen can improve outcomes remains a question for clinical testing.
| Item | Details |
|---|---|
| Study stage | Planned Phase 1/2 clinical trial |
| Trial leadership | Genmab |
| Treatment components | Petosemtamab, INCB161734 and chemotherapy |
| Target population | Patients with advanced KRAS G12D-mutated colorectal cancer |
How INCB161734 fits the proposed treatment
Incyte’s description of INCB161734 identifies the drug as an investigational, oral, selective inhibitor of G12D-mutated KRAS. That mechanism directly matches the mutation used to define the planned trial’s patient population.
Incyte explains that KRAS proteins act as molecular switches controlling signaling pathways involved in cell survival and proliferation. Its medical information also identifies G12D as a frequently occurring KRAS mutation with a high incidence in pancreatic and colorectal cancers.
The medical information describes the drug and its biological target. It does not establish the timing or results of the newly announced Genmab combination study.
Conclusion
The next step for Genmab and Incyte is clinical evaluation of the proposed combination. The collaboration sets out what the companies intend to test, while evidence of patient benefit remains to be established.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
